KFO309 - The clinical research unit Virus Induced Lung injury

All News / Events

ATS 2018 Awardees


The abstract of Dr. Christina Malainou, a member of the Herold lab, was chosen to receive an Abstract Scholarship for the 2018 ATS International Conference in San Diego.

The Abstract has the title "Depletion Of The Resident Alveolar Macrophage Pool Upon Influenza Virus Infection Is Death Ligand-Dependent And Contributes To Disease Severity"

Ivonne Vazquez-Armendariz was selected to receive the International Trainee Travel Scholarship Award 2018 of the American Thoracic Society. 

Progress Reports 2018


ECCPS Seminar Room

Aulweg 130

35392 Gießen


Date Projects
Feb, 23th
12:45 - 14:45 h
P1 (Bauer/Weber) and
P2 (Peteranderl/Becker/Herold)
Apr 13th,
12:45 - 14:45 h
P3 (Ziebuhr/Kracht) and
P5 (Vadász/Samakovlis)
Aug 17th,
12:00 - 15:00 h
P6 (Morty/Friebertshäuser/Ehrhardt),
P7 (Günther/Bellusci) and
P8 (Herold/Braun)
Dec, 7th,
12:45 - 14:45 h
 Z1 (Hain/Goesmann/
Wilhelm/Lohmeyer) and
Amit Shresta
(early career funding report)

Kampf dem Lungenversagen


Virus-Infektionen sind bei Kindern und Erwachsenen ein häufiges Krankheitsbild. Gar nicht so selten kommt es dabei zu einer Lungenentzündung oder im schlimmsten Fall zu lebensbedrohlichem akutem Lungenversagen. Wirksame Therapien fehlen bislang. Ein Team um die Gießener Professorin Susanne Herold wird ab sofort an der Erforschung der Krankheit und der Entwicklung neuer Diagnostik- und Behandlungsmethoden arbeiten – mithilfe von 4,3 Millionen Euro der Deutschen Forschungsgemeinschaft.

Impressions of the KFO309 get together - 21.04.2017


Wie Coronaviren Zellen umprogrammieren


Interdisziplinäres Team der Universität Gießen identifiziert epigenetische Kontrollmechanismen der Genantwort der Wirtszelle bei Infektionen mit dem Coronavirus 229E

Research Acceleration Initiative (RAI) grant 2022 from CSL Behring for Elie El Agha

Tuesday, 27 September 2022

Seven medical researchers have been awarded a CSL Research Acceleration Initiative (RAI) partnership, including up to an AU$500,000 investment in each program over two years, to fast-track the discovery of innovative biotherapies to address unmet medical needs.

One of the awardess is KFO309 member Elie El Agha for his research program that is focused on novel cellular and molecular pathways implicated in the pathobiology of idiopathic pulmonary fibrosis; a progressive lung disease that currently has no cure.